Information
-
Trademark
-
85021938
-
Serial Number
85021938
-
Registration Number
4133826
-
International Classifications
-
Filing Date
April 23, 2010
14 years ago
-
Registration Date
May 01, 2012
12 years ago
-
Transaction Date
January 15, 2019
5 years ago
-
Status Date
December 07, 2018
6 years ago
-
Published for Opposition Date
February 14, 2012
12 years ago
-
Location Date
May 01, 2012
12 years ago
-
Status Code
710
-
Current Location
PUBLICATION AND ISSUE SECTION
Employee Name
ERVIN, INGA MARIE
-
Attorney Docket Number
140998
Attorney Name
Zachary A. Aria
Law Office Assigned Location Code
M20
-
Owners
Mark Drawing Code
3000
Mark Identification
G
Case File Statements
- CC0000: Color is not claimed as a feature of the mark.
- DM0000: The mark consists of the letter "G" with a dot.
- GS0051: Gene therapy systems; pharmaceutical products for the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; biological preparations for medical and clinical use, namely, the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and cell therapy; gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, disease caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone disease, inherited disorders, genetic disorders and single gene disorders; chemical reagents for clinical or medical use, namely, vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes; gene therapy and prophylaxis products, namely, gene transfer for the treatment of the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers
- GS0441: Medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders through gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation
Case File Event Statements
-
12/7/2018 - 6 years ago
43 - CANCELLED SEC. 8 (6-YR)
Type: C8..
-
5/1/2017 - 7 years ago
42 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Type: REM1
-
7/8/2014 - 10 years ago
41 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Type: ARAA
-
7/8/2014 - 10 years ago
40 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Type: REAP
-
7/2/2014 - 10 years ago
39 - AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Type: ASGN
-
5/1/2012 - 12 years ago
38 - REGISTERED-PRINCIPAL REGISTER
Type: R.PR
-
2/14/2012 - 12 years ago
37 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Type: NPUB
-
2/14/2012 - 12 years ago
36 - PUBLISHED FOR OPPOSITION
Type: PUBO
-
1/25/2012 - 12 years ago
35 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Type: NONP
-
1/10/2012 - 12 years ago
34 - LAW OFFICE PUBLICATION REVIEW COMPLETED
Type: PREV
-
1/6/2012 - 12 years ago
33 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
1/6/2012 - 12 years ago
32 - EXAMINER'S AMENDMENT ENTERED
Type: XAEC
-
1/6/2012 - 12 years ago
31 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Type: GNEN
-
1/6/2012 - 12 years ago
30 - EXAMINERS AMENDMENT E-MAILED
Type: GNEA
-
1/6/2012 - 12 years ago
29 - EXAMINERS AMENDMENT -WRITTEN
Type: CNEA
-
1/5/2012 - 12 years ago
28 - PREVIOUS ALLOWANCE COUNT WITHDRAWN
Type: ZZZX
-
12/20/2011 - 13 years ago
27 - WITHDRAWN FROM PUB - OG REVIEW QUERY
Type: PBCR
-
12/6/2011 - 13 years ago
26 - LAW OFFICE PUBLICATION REVIEW COMPLETED
Type: PREV
-
11/21/2011 - 13 years ago
25 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
11/4/2011 - 13 years ago
24 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
11/4/2011 - 13 years ago
23 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
11/4/2011 - 13 years ago
22 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
5/9/2011 - 13 years ago
21 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
5/9/2011 - 13 years ago
20 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
5/9/2011 - 13 years ago
19 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
4/13/2011 - 13 years ago
18 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
4/13/2011 - 13 years ago
17 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
4/13/2011 - 13 years ago
16 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
2/4/2011 - 13 years ago
15 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
2/4/2011 - 13 years ago
14 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
2/4/2011 - 13 years ago
13 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
1/15/2011 - 13 years ago
12 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
1/15/2011 - 13 years ago
11 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
1/12/2011 - 13 years ago
10 - ASSIGNED TO LIE
Type: ALIE
-
12/22/2010 - 14 years ago
9 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
12/20/2010 - 14 years ago
8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
6/23/2010 - 14 years ago
7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
6/23/2010 - 14 years ago
6 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
6/23/2010 - 14 years ago
5 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
6/22/2010 - 14 years ago
4 - ASSIGNED TO EXAMINER
Type: DOCK
-
4/30/2010 - 14 years ago
3 - NOTICE OF DESIGN SEARCH CODE MAILED
Type: MDSC
-
4/29/2010 - 14 years ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Type: NWOS
-
4/27/2010 - 14 years ago
1 - NEW APPLICATION ENTERED IN TRAM
Type: NWAP